Promising Immunotherapies against COVID-19

被引:4
作者
Guo, Haodong [1 ]
Zhou, Lili [1 ]
Ma, Zhenyu [1 ]
Tian, Zhixin [1 ]
Zhou, Fangfang [1 ]
机构
[1] Soochow Univ, Inst Biol & Med Sci, Jiangsu Key Lab Infect & Immun, Suzhou 215123, Jiangsu, Peoples R China
基金
美国国家科学基金会; 中国国家自然科学基金;
关键词
convalescent plasma; coronavirus disease 2019; COVID-19; cytokine storm; immunotherapy; interferon; severe acute respiratory syndrome coronavirus 2; RESPIRATORY SYNDROME CORONAVIRUS; CYTOKINE STORM; III INTERFERONS; VACCINE; PROTEIN; SPIKE; RIBAVIRIN; RESPONSES; EFFICACY; EVASION;
D O I
10.1002/adtp.202100044
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a severe pandemic and deeply affected the livelihood of people worldwide. In response to the pandemic, researchers have been rapidly studying different aspects of COVID-19, such as virus detection, vaccinations, and epidemiological aspects of the disease. It has been reported that SARS-CoV-2 can induce uncontrolled inflammation and cause a lack of antiviral response, thereby aggravating the disease. Therefore, recovery of immune functions is key to COVID-19 treatment. Many clinical trials are exploring suitable therapies, and some progress has been made. Early administration of interferons may prevent COVID-19 exacerbation and/or promotes recovery from the diseases. Inhibitors of inflammation can prevent cytokine storms and multi-organ damage. Convalescent plasma containing neutralizing antibodies has played an important role in therapeutic options at the beginning of the pandemic owing to the lack of other effective methods. To aid the development of treatment options for COVID-19, this review focuses on immunotherapies, including treatment with interferons, inhibition of pro-inflammatory mechanisms, and the use of convalescent plasma.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] The Effect of COVID-19 and Vaccination against COVID-19 on Patients with Psoriasis
    Tamer, Funda
    Aypek, Yagmur
    Aksakal, Ahmet B.
    ROMANIAN JOURNAL OF MILITARY MEDICINE, 2024, 127 (02) : 105 - 110
  • [32] COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants
    Padasas, Bill Thaddeus
    Espano, Erica
    Kim, Sang-Hyun
    Song, Youngcheon
    Lee, Chong-Kil
    Kim, Jeong-Ki
    IMMUNE NETWORK, 2023, 23 (02)
  • [33] Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms
    Bayat, Maryam
    Asemani, Yahya
    Najafi, Sajad
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 97
  • [34] Immunotherapies in pediatric neurology during the COVID-19 pandemic: A pragmatic approach
    Reddy, Chaithanya
    Bhagwat, Chandana
    Saini, Arushi
    JOURNAL OF PEDIATRIC NEUROSCIENCES, 2022, 17 (01) : 12 - 16
  • [35] Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials
    Farhangnia, Pooya
    Dehrouyeh, Shiva
    Safdarian, Amir Reza
    Farahani, Soheila Vasheghani
    Gorgani, Melika
    Rezaei, Nima
    Akbarpour, Mahzad
    Delbandi, Ali-Akbar
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 109
  • [36] Stem Cell Based Therapy Option in COVID-19: Is It Really Promising?
    Irmak, Duygu Koyuncu
    Darici, Hakan
    Karaoz, Erdal
    AGING AND DISEASE, 2020, 11 (05): : 1174 - 1190
  • [37] Harnessing immunological targets for COVID-19 immunotherapy
    Mehata, Abhishesh Kumar
    Viswanadh, Matte Kasi
    Priya, Vishnu
    Vikas
    Muthu, Madaswamy S.
    FUTURE VIROLOGY, 2021, 16 (09) : 619 - 640
  • [38] Activated neutrophils in the initiation and progression of COVID-19: hyperinflammation and immunothrombosis in COVID-19
    Zhao, Xinyi
    Zhou, Lijin
    Kou, Yan
    Kou, Junjie
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (03): : 1454 - 1468
  • [39] Pathogenic Mechanism and Multi-omics Analysis of Oral Manifestations in COVID-19
    Hao, Ming
    Wang, Dongxu
    Xia, Qianyun
    Kan, Shaoning
    Chang, Lu
    Liu, Huimin
    Yang, Zhijing
    Liu, Weiwei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [40] COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes?
    Vanden Eynde, Jean Jacques
    PHARMACEUTICALS, 2021, 14 (07)